New Delhi, 22 July 2024: The Indian Patent Office’s rejection of Johnson & Johnson’s (J&J) application for the paediatric version of its anti-tuberculosis (TB) drug, bedaquiline, is likely to have broader implications for access to cost-effective TB treatment,......
View Details

Related News

• During FY24, Export and import of bulk drugs was ₹39,632 Crore and ₹37,722 Crore: Economic Survey 2024 (22-07-2024)

---

• Pharma MNCs seek relief from price control for patented drugs (22-07-2024)

---

• Number of overcharging cases and demand raised by NPPA declines in 2023-24 (22-07-2024)

---

• FPME calls for trial run ahead of February 2025 track and trace implementation (22-07-2024)

---

• Health facilities employing unqualified staff, verify credentials: Delhi Medical Council (22-07-2024)

---

• NCB seizes 3,000 Codeine cough syrup bottles, three held (21-07-2024)

---

• DCA seizes banned 'Ofloxacin and Ornidazole' Suspension (21-07-2024)

---

• Telangana: Medical Devices Park expansion in limbo (21-07-2024)

---

• Madras High Court notice to Center on three new criminal laws (21-07-2024)

---

• Blood cancer medication makes radiation therapy on brain tumours more effective, study reveals (21-07-2024)

---